LONA:NASDAQ
LeonaBio Inc
3,57 USD
arrow_upward
+1,71%(+0,060) 1 D
3,59 USD
arrow_upward
+0,56% (+0,020)bedtimeEtter stengetid
Stengt: 30. sep., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for LONA …
Åpne
3,51 USD
Høy
3,59 USD
Lav
3,31 USD
Markedsverdi
33,64 mill.
Snittvolum
115,33k
Volum
40,26k
52 u høy
14,19 USD
52 u lav
2,21 USD
EPS
−19,72 USD
Beta
2,05
Utestående aksjer
9,42 mill.
Antall ansatte
19
Åpne
3,51 USD
Høy
3,59 USD
Lav
3,31 USD
Markedsverdi
33,64 mill.
Snittvolum
115,33k
Volum
40,26k
52 u høy
14,19 USD
52 u lav
2,21 USD
EPS
−19,72 USD
Beta
2,05
Utestående aksjer
9,42 mill.
Antall ansatte
19
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 1 døgn siden
Dow faller 130 poeng etter at amerikanske statsrenter når flerårige høyder
Simply Wall Street
·
for 32 minutter siden
Is NetApp (NTAP) Becoming More Central To AI Infrastructure With Novus?
Kalkine Media
·
for 1 time siden
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK)
Barchart.com
·
for 1 time siden
What You Need To Know Ahead of Nasdaq's Earnings Release
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Om LeonaBio Inc
Administrerende direktør-
Ansatte19
Grunnlagt2011
HovedkontorBothell, Washington, USA
Sektor-
Nettstedleonabio.com